Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial.

Masao KodaShiro ImagamaHiroaki NakashimaSadayuki ItoNaoki SegiJun OuchidaKota SudaSatoko Harmon MatsumotoMiki KomatsuToshiki EndoShinsuke SuzukiSatoshi InamiHaruki UedaMasayuki MiyagiGen InoueMasashi TakasoKeiji NagataHiroshi YamadaNaosuke KameiToshio NakamaeHidenori SuzukiNorihiro NishidaMasahiro FunabaGentaro KumagaiTakeo FuruyaYu YamatoToru FunayamaHiroshi TakahashiMasashi Yamazaki

Published in: Stem cell research & therapy (2024)

jRCT, JRCT1080224764. Registered 03 July 2019, https://jrct.niph.go.jp/latest-detail/jRCT1080224764 .

Keyphrases

spinal cord injury
clinical trial
induced apoptosis
endothelial cells
cell cycle arrest
spinal cord
neuropathic pain
high dose
endoplasmic reticulum stress
induced pluripotent stem cells
pluripotent stem cells
phase ii
cell death
open label
signaling pathway